FINWIRES · TerminalLIVE
FINWIRES

VNET Group's Order Wins Improve Growth Visibility, Morgan Stanley Says

By

VNET Group's (VNET) recent 500 megawatt order win adds more visibility to its capacity ramp up over the next three years, Morgan Stanley said in a Tuesday note.

As most orders in the first half of 2025 were delivered, move-ins slowed in the first half of 2026, but should begin to re-accelerate in the second half as VNET starts delivering large orders secured since Q4 2025. Q1 2027 is expected to see even faster move-ins, and the analysts said they expect Q2 revenue and EBITDA to remain stable quarter-over-quarter, according to the note.

Following the 500 MW order win from one hyperscaler, VNET is confident in winning more orders from another hyperscaler's recent tender. The company expects stable prices for now and sees potential upside if supply remains constrained, the brokerage said.

VNET is actively seeking more gigawatt-scale campuses within Inner Mongolia and the Yangtze Delta, as well as potentially expanding into another two to three new nodes within the East Data West Compute zones, according to the note.

Morgan Stanley kept an overweight rating on VNET Group with a price target of $16.

Shares of VNET Group rose more than 8% in Wednesday trading.

Price: $10.72, Change: $+0.80, Percent Change: +8.06%

Related Articles

Wire

Ooma Fiscal Q1 Adjusted Earnings, Revenue Rise; Shares Gain After Hours

Ooma (OOMA) reported fiscal Q1 adjusted earnings late Tuesday of $0.35 per diluted share, up from $0.20 a year earlier.Analysts polled by FactSet expected $0.32.Revenue in the three months ended April 30 rose to $81.1 million from $65 million a year earlier.Analysts surveyed by FactSet expected $79.8 million.Ooma expects fiscal Q2 adjusted EPS of $0.33 to $0.34 on revenue of $81.6 million to $82.3 million.Analysts polled by FactSet expect EPS of $0.31 on revenue of $80.2 million.The company boosted fiscal 2027 adjusted EPS guidance to $1.29 to $1.34 on revenue of $326 million to $328.5 million. Prior guidance was EPS of $1.26 to $1.31 on revenue of $321 million to $325 million.Analysts surveyed by FactSet expect EPS of $1.29 on revenue of $322.8 million.Ooma shares rose 4.8% in after-hours trading.

$OOMA
Wire

Jade Biosciences Says First Participant Dosed in First-in-Human Phase 1 Trial of JADE201

Jade Biosciences (JBIO) said late Tuesday the first participant has been dosed in a first-in-human phase 1 clinical trial of JADE201, an investigational, half-life extended, afucosylated monoclonal antibody.The first-in-human trial is a placebo-controlled study assessing single ascending doses of JADE201 in participants with rheumatoid arthritis, according to a statement.Jade said interim phase 1 data in rheumatoid arthritis anticipated in 2027 are expected to inform indication prioritization across potential autoimmune indications supported by B cell activating factor receptor biology.

$JBIO
Wire

Zscaler Fiscal Q3 Adjusted Earnings, Revenue Rise; Q4 Guidance Set

Zscaler (ZS) reported fiscal Q3 adjusted earnings late Tuesday of $1.08 per diluted share, up from $0.84 a year earlier.Analysts polled by FactSet expected $1.01.Revenue for the three months ended April 30 was $850.5 million, up from $678 million a year earlier.Analysts surveyed by FactSet expected $835.6 million.For fiscal Q4, the company expects adjusted EPS of $1.08 to $1.09 on revenue of $875 million to $878 million. Analysts expect EPS of $1.03 on revenue of $878.6 million.For the full-year fiscal 2026, the company now expects adjusted EPS of $4.10 to $4.11 on revenue of $3.329 billion to $3.332 billion. It earlier expected adjusted EPS of $3.99 to $4.02 on revenue of $3.31 billion to $3.32 billion.Analysts expect EPS of $4.01 on revenue of $3.32 billion.

$ZS